Perspective Therapeutics CATX
NYSE CATX
$2.98 -0.14 (-4.49%)
As of: Sep 9, 2026 · 3:59 PM EDT

Perspective Therapeutics (CATX) Assets (2011 - 2026)

Perspective Therapeutics' (CATX) quarterly Assets came in at $392.0 million in Q2 2026, up 26.16% year-over-year from $310.7 million in Q2 2025, and down 4.56% quarter-over-quarter from $410.8 million in Q1 2026.

Analysis

Perspective Therapeutics (CATX) Assets (2011 - 2026) Analysis & Trends

Perspective Therapeutics has disclosed Assets across 16 years of filings, most recently posting $392.0 million for Q2 2026.

  • In Q2 2026, Assets rose 26.16% year-over-year to $392.0 million; the TTM figure through Jun 2026 stood at $392.0 million (up 26.16% YoY), while the FY2025 annual figure was $267.0 million, down 21.73% from the prior year.
  • Assets came in at $392.0 million for Q2 2026 at Perspective Therapeutics, down from $410.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $410.8 million in Q1 2026 to a low of $58.1 million in Q4 2022.
  • Average Assets over 5 years is $228.3 million, with a median of $272.6 million recorded in 2024.
  • Year-over-year, Assets jumped 253.93% in 2024 and slipped 24.63% in 2025.
  • Over 5 years, Assets stood at $58.1 million in 2022, then soared by 68.51% to $97.9 million in 2023, then surged by 248.45% to $341.1 million in 2024, then slipped by 21.73% to $267.0 million in 2025, then soared by 46.84% to $392.0 million in 2026.
  • Per Business Quant data, the three most recent Assets figures were $392.0 million in Q2 2026, $410.8 million in Q1 2026, and $267.0 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Assets (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 95.64 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 49.36 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 27.42 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 41.73 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 10.03 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 10.96 Bn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 5.56 Bn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 32.09 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 2.10 Bn
10 Perspective Therapeutics 358.23 Mn 358.23 Mn - 392.03 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 392.03 Mn
Mar 31, 2026 410.77 Mn
Dec 31, 2025 266.97 Mn
Sep 30, 2025 294.83 Mn
Jun 30, 2025 310.73 Mn
Mar 31, 2025 329.35 Mn
Dec 31, 2024 341.10 Mn
Sep 30, 2024 391.15 Mn
Jun 30, 2024 385.92 Mn
Mar 31, 2024 278.29 Mn
Dec 31, 2023 97.89 Mn
Sep 30, 2023 110.52 Mn
Jun 30, 2023 120.15 Mn
Mar 31, 2023 127.65 Mn
Dec 31, 2022 58.09 Mn
Sep 30, 2022 62.54 Mn
Jun 30, 2022 64.44 Mn
Mar 31, 2022 66.11 Mn
Dec 31, 2021 67.25 Mn
Sep 30, 2021 68.71 Mn